Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta analysis of a randomised, controlled, adaptive platform study (PLATCOV)

4

Phrutsamon Wongnak¹, William HK Schilling^{1,2}, Podjanee Jittamala^{1,3}, Simon Boyd^{1,2}, Viravarn Luvira⁴,
Tanaya Siripoon⁴, Thundon Ngamprasertchai³, Elizabeth M Batty^{1,2}, Shivani Singh^{1,2}, Jindarat Kouhathong¹, Watcharee Pagornrat¹, Patpannee Khanthagan¹, Borimas Hanboonkunupakarn^{1,4},
Kittiyod Poovorawan^{1,4}, Mayfong Mayxay^{2,5,6}, Kesinee Chotivanich^{1,4}, Mallika Imwong^{1,7}, Sasithon Pukrittayakamee^{1,4}, Elizabeth A Ashley^{2,5}, Arjen M Dondorp^{1,2}, Nicholas PJ Day^{1,2}, Mauro M Teixeira⁸,
Watcharapong Piyaphanee⁴, Weerapong Phumratanaprapin⁴, Nicholas J White^{1,2,†}, James A Watson^{2,9,†}, on behalf of the PLATCOV Collaborative Group[‡]

12

*Correspondence to: James A Watson, Centre for Tropical Medicine and Global Health, Nuffield Department
 of Medicine, University of Oxford, New Richards Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7LG,
 UK, jwatowatson@gmail.com; Nicholas J White, Mahidol Oxford Tropical Medicine Research Unit, Faculty of
 Tropical Medicine, Mahidol University, Bangkok 10400, Thailand, <u>nickw@tropmedres.ac</u>

- 17
- 18 [†]Equal contribution
- Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok,
 10400, Thailand;

² Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, New
 Richards Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7LG, UK;

- ³ Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok,
- 24 Thailand;
- ⁴ Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok,
 Thailand;
- ⁵ Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital,
 Vientiane, Lao P.D.R.;
- ⁶ Institute for Research and Education Development, University of Health Sciences, Vientiane, Lao P.D.R.;
- ⁷ Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University,
 Bangkok, Thailand.;
- ⁸ Clinical Research Unit, Center for Advanced and Innovative Therapies, Universidade Federal de Minas Gerais,
 Brazil;
- ⁹ Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.
- 35 ‡A full list of the PLATCOV Collaborative Group is given in the appendix.
- 36
- 37

38 Abstract

Background Effective antiviral drugs prevent hospitalisation and death in COVID-19. Antiviral efficacy can be assessed efficiently in-vivo by measuring rates of SARS-CoV-2 clearance estimated from serial viral genome densities quantitated in nasopharyngeal or oropharyngeal swab eluates. We carried out an individual patient data meta-analysis of unblinded arms in the PLATCOV platform trial to characterise changes in viral clearance kinetics and infer optimal design and interpretation of antiviral pharmacometric evaluations. PLATCOV is registered at ClinicalTrials.gov, NCT05041907.

45

53

Methods Serial viral density data were analysed from symptomatic, previously healthy, adult patients (within 4 days of symptom onset) enrolled in a large multicentre randomised adaptive pharmacodynamic platform 48 trial (PLATCOV) comparing antiviral interventions for SARS-CoV-2. Viral clearance rates over one week were 49 estimated under a hierarchical Bayesian linear model with B-splines used to characterise temporal changes in 50 enrolment viral densities and clearance rates. Bootstrap re-sampling was used to assess the optimal duration 51 of follow-up for pharmacometric assessment, where optimal is defined as maximising the expected z-score 52 when comparing effective antivirals with no treatment.

- 54 Results Between 29 September 2021 and 20 October 2023, 1262 patients were randomised. Unblinded data 55 were available from 800 patients (16,818 oropharyngeal viral gPCR measurements) of whom 63% (504/800) 56 were female. 98% (783/800) had received at least one vaccine dose and over 88% (703/800) were fully 57 vaccinated. SARS-CoV-2 viral clearance was biphasic (bi-exponential). The first phase (α) was accelerated by 58 effective interventions. For all the effective interventions studied, maximum discriminative power (maximum 59 expected z-score) was obtained when evaluating serial data from the first 5 days after enrolment. Over the 60 two-year period studied, median viral clearance half-lives estimated over 7 days have shortened from 16.6 61 hours (interguartile range [IQR]: 15.3 to 18.2) in September 2021 to 9.2 hours (IQR: 8.0 to 10.6) in October 62 2023 in patients receiving no antiviral drugs, equivalent to a relative reduction of 44% [95% credible interval 63 (CrI): 19 to 64%]. A parallel trend was observed in treated patients. In the 158 patients randomised to ritonavirboosted nirmatrelvir (3,380 gPCR measurements), the median viral clearance half-life declined from 6.4 hours 64 65 (IQR: 5.7 to 7.3) in June 2022 to 4.8 hours (IQR: 4.2 to 5.5) in October 2023, a relative reduction of 26% [95%Crl: 66 -4 to 42%].
- 67

68 **Conclusions** SARS-CoV-2 viral clearance kinetics in symptomatic vaccinated individuals have accelerated 69 substantially over the past two years. Antiviral efficacy in COVID-19 can now be assessed efficiently in-vivo 70 using serial qPCRs from duplicate oropharyngeal swab eluates taken daily for 5 days after drug administration.

71

72 **Funding** Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.

74 Background

75 Effective SARS-CoV-2 antivirals taken early in the course of COVID-19 illness accelerate viral clearance, hasten 76 symptom resolution, reduce transmission, and lower the probability of progression to severe disease [1–4]. 77 Several small molecule drugs and monoclonal antibodies have proven antiviral efficacy in COVID-19, although 78 monoclonal antibodies are no longer used widely as immune evasion resulting from viral evolution has reduced 79 or abrogated their antiviral effects. Currently the most effective approved small molecule antiviral drug is 80 ritonavir-boosted nirmatrelvir, a main (3C-like) protease inhibitor [5]. Nirmatrelvir reduces progression to 81 severe disease in an unvaccinated high-risk population by around 90% [3]. But the combination drug is 82 expensive, ritonavir is contraindicated in many individuals because of drug-drug interactions, and ritonavir-83 boosted nirmatrelvir frequently results in troubling dysgeusia [3]. The development of better tolerated drugs 84 (for example ensitrelvir, also a main protease inhibitor [6]) which could be administered more widely would 85 be of considerable public health value, particularly if they were affordable. To guide policies and practices the 86 antiviral activities of new drugs need to be compared against current treatments. Antiviral interventions can 87 be assessed and compared using acceleration in the rate of viral clearance as a surrogate for clinical benefit 88 [7–9]

90 The natural history of SARS-CoV-2 infection has changed markedly over the past four years since the beginning 91 of the pandemic [10]. Serious clinical outcomes, notably life-threatening inflammatory pneumonitis, are now 92 very rare. As a result, it has become very difficult to demonstrate clinical efficacy for new antiviral drugs 93 because the required trial sample sizes have become prohibitively large. This was illustrated in the very large 94 PANORAMIC trial of molnupiravir in the UK where only 203 primary events were observed in >25,000 95 randomised at-risk patients [11]. An alternative approach is to use rates of in-vivo viral clearance to 96 characterise and compare antiviral efficacies [12]. This is relatively straightforward and requires orders of 97 magnitude fewer patients [13]. PLATCOV is an ongoing multicentre phase 2 adaptive, open label, randomised, 98 pharmacometric platform trial in symptomatic low risk adults with COVID-19 (NCT05041907) [13]. Results from 99 this trial have demonstrated the utility of this approach in identifying ineffective drugs, and assessing and 100 comparing those which are clinically effective [5, 13–16].

101

113

89

102 Viral clearance in COVID-19 follows an approximate bi-exponential (biphasic) decay pattern [17–19]. Previous 103 studies have shown that effective antiviral interventions increase the rate of viral clearance in the first phase 104 [12, 20]. The effect of antivirals on the second phase is less clear and of lesser importance as viral densities are 105 usually fairly low (i.e., unlikely to be transmissible), close to the limit of detection, and clear spontaneously in 106 individuals who are not immunocompromised. The majority of small molecule drugs are given for up to 5 days 107 (e.g., remdesivir, molnupiravir, ritonavir-boosted nirmatrelvir) and have short elimination half-lives. Thus, the 108 primary aim of the PLATCOV trial was to characterise and compare antiviral effects during the first phase of 109 viral clearance. For this reason, the primary endpoint included measured viral densities only up until day 7. In 110 this paper we present an analysis of viral clearance in all patients with unblinded data in the PLATCOV study in 111 order to characterise temporal changes in viral kinetics and re-assess the optimal approach for characterising 112 and comparing antiviral effects in-vivo.

114 Methods

115 The PLATCOV trial

PLATCOV is an ongoing, open-label, multicentre, phase 2, randomised, controlled, adaptive pharmacometric
 platform trial in Thailand, Brazil, Pakistan, and Laos. The trial provides a standardised quantitative comparative
 method for in-vivo assessment of potential antiviral treatments in adults at low risk with early symptomatic
 COVID-19. The primary endpoint is the rate of viral genome clearance estimated under a linear model fitted to
 the log viral load (measured by qPCR in daily duplicate oropharyngeal viral swab eluates) data currently

- sampled on Day 0 and over 7 days of follow-up (8 days in total), denoted α_{0-7} . All patients receive symptomatic
- 122 treatment (mainly paracetamol).
- 123 PLATCOV is coordinated and monitored by the Mahidol Oxford Tropical Medicine Research Unit (MORU) in
- Bangkok. The trial was overseen by a trial steering committee and was conducted according to Good Clinical
- 125 Practice principles. PLATCOV is registered at ClinicalTrials.gov, NCT05041907.
- 126

127 Ethics statement

128 The trial was approved by the Oxford University Tropical Research Ethics Committee (Oxford, UK) and ethics 129 committees in each country. The results were reviewed regularly by a data and safety monitoring board. In 130 Thailand the trial was approved by the Faculty of Tropical Medicine Ethics Committee, Mahidol University, 131 (reference TMEC 21-058); in Brazil by the Research Ethics Committee of the Universidade Federal de Minas 132 Gerais (COEP-UFMG, Minas Gerais, Brazil, COEP-UFMG) and National Research Ethics Commission- (CONEP, 133 Brazil, COEP-UFMG and CONEP Ref: CAAE:51593421.1.0000.5149); in Laos by the National Ethics Committee 134 for Health Research (NECHR, Lao People's Democratic Republic, Submission ID 2022.48) and the Food & Drugs 135 Department (FDD, Lao People's Democratic Republic, 13066/FDD_12Dec2022); in Pakistan by the National 136 Bioethics Committee (NBC No.4-87/COVID-111/22/842) the Ethics Review Committee (ERC 2022-7496-21924)

and the Drug Regulatory Authority (DRAP Ref: No.0318/2022-CT (PS)).

139 Participants

140 Eligible participants were previously healthy adults aged 18–50 years who gave fully informed consent for full 141 participation in the study. The entry criteria were: (i) SARS-CoV-2 positive as defined either as a nasal lateral 142 flow antigen test that became positive within 2 minutes (STANDARD Q COVID-19 Ag Test, SD Biosensor, Suwon-143 si, South Korea) or a positive PCR test with a cycle threshold value less than 25 (all viral gene targets) within 144 the previous 24 h (both these tests ensure the majority of recruited patients have high viral densities); (ii) 145 reported symptoms of COVID-19 for less than 4 days (<96 h); (iii) oxygen saturation on room air ≥96% 146 measured by pulse oximetry at the time of screening; (iv) unimpeded in activities of daily living; (v) agreed to 147 adhere to all procedures, including availability and contact information for follow-up visits.

148

149 Exclusion criteria included taking any concomitant medications or drugs, chronic illness or condition requiring 150 long-term treatment or other clinically significant comorbidity, laboratory abnormalities at screening 151 (haemoglobin <8 g/dL, platelet count <50 000/µL, abnormal liver function tests, and estimated glomerular 152 filtration rate <70 mL/min per 1.73 m²), pregnancy (a urinary pregnancy test was performed in females), 153 actively trying to become pregnant, lactation, contraindication or known hypersensitivity to any of the 154 proposed therapeutics, currently participating in a COVID-19 therapeutic or vaccine trial, or evidence of 155 pneumonia (although imaging was not required). After a detailed explanation of study procedures and 156 requirements all patients provided fully informed written consent.

157

Block randomisation was performed for each site via a centralised web-based application. At enrolment, after obtaining fully informed consent and entering the patient details, the app provided the study drug allocation. The no study drug group (unblinded, no placebos were used) comprised a minimum proportion of 20% of patients at all times, with uniform randomisation ratios applied across the active treatment groups. The laboratory team were masked to treatment allocation and the clinical investigators were masked to the virology results until the study group was terminated. Apart from the trial statisticians (JAW and PW), the clinical investigators were all masked to the quantitative PCR (qPCR) results.

165

Patients were included in this analysis if they had been randomised to a currently unblinded treatment arm and had at least two days of follow-up (i.e., sufficient to estimate a clearance slope).

169 Procedures

All treatments were directly observed. Oropharyngeal swabs were taken as follows by trained study nurses. A
 flocked swab (Thermo Fisher MicroTest[®] [Thermo Fisher, Waltham, MA, USA] and later COPAN FLOQSwabs[®]
 [COPAN Diagnostics, Murrieta, CA, USA]) was rotated against the tonsil through 360° four times and placed in
 Thermo Fisher M4RT (Thermo Fisher, Waltham, MA, USA) viral transport medium (3 mL). Swabs were
 transferred at 4–8°C, aliguoted, and then frozen at –80°C within 48 h.

175

176 On day 0, following randomisation, four separate swabs (two swabs from each tonsil) were taken. Separate 177 swabs from each tonsil were then taken once daily from day 1 to day 7, on day 10, and on day 14 (total of 22 178 swabs). Each swab was processed and tested separately. Vital signs were recorded three times daily by the 179 patient (initial vital signs on the first day were recorded by the study team), and symptoms and any adverse 180 effects were recorded daily. The TaqCheck SARS-CoV-2 Fast PCR Assay (Applied Biosystems, Thermo Fisher 181 Scientific, Waltham, MA, USA) quantitated viral density (RNA copies per mL). This multiplexed real-time PCR 182 method detects the SARS-CoV-2 N and S genes, and human RNase P gene in a single reaction. RNase P provides a measure of the human cell content in the swab eluate, thus allowing for adjustment for variation in intra-183 184 cellular viral RNA. Whole-genome sequencing was performed to identify viral variants and allocate genotypes 185 (appendix pages 2-4).

187 Drugs evaluated

The drugs or monoclonal antibodies evaluated in the platform were ivermectin (until 11th April 2022); remdesivir (until 10th June 2022); casirivimab/imdevimab (Thailand only, until 20th October 2022); favipiravir (until 30th October 2022); molnupiravir (until 22nd February 2023); fluoxetine (until 8th May 2023, data not included in this analysis); tixagevimab/cilgavimab (until 4th July 2023, data not included in this manuscript); nitazoxanide (Brazil, Laos and Pakistan, from 18th January 2022, ongoing); ensitrelvir (Thailand and Laos only, from 17th March 2023, ongoing); and ritonavir-boosted nirmatrelvir (from 6th June 2022, ongoing as positive control). All treatment doses were either directly observed or video observed.

195

186

196 Statistical analysis

197 Data pre-processing

198 Oropharyngeal eluate viral densities were quantified by PCR on 96-well plates. Each plate contained 10 or 12 199 ATCC controls (Manassas, VA, USA; these are heat-inactivated SARS-CoV-2 viruses [VR-1986HK strain 2019-200 nCoV/USAWA1/2020]) varying from 10 to 10^6 copies per mL. We fitted a linear mixed-effects model to all ATCC 201 control data from all available plates (using R package Ime4 version 1.1.34 [21]) with the genome copies per mL on the log₁₀ scale (i.e., a linear relationship between CT values and known log₁₀ genomes per ml). The model 202 203 included fixed effects on the slope and intercept by laboratory (reference laboratory was Thailand), and 204 random effects on the slope and intercept by plate. Visual checks were done to make sure that controls on all 205 plates were in a reasonable range. The mixed-effects model was then used to transform the observed CT values 206 for the oropharyngeal eluates into log₁₀ genomes per mL. A CT value of 40 was considered left censored and 207 the plate specific censoring value was used in subsequent analyses. Appendix page 7 shows the estimated 208 standard curves and the model residuals by laboratory.

209

210 Baseline viral densities

The baseline viral density was defined as the geometric mean of the oropharyngeal eluate SARS CoV-2 densities from the four independent swabs taken before randomisation. Temporal trends in the baseline viral densities

213 were characterised using generalised additive models (GAM) with penalised splines, as implemented in the

214 *mgcv* package version 1.9.0 [22]. As the timing of patient recruitment relative to their onset of symptoms could

- 215 have also changed over time (and this could affect baseline viral densities), the temporal effect was stratified
- by the reported number of days since symptom onset. Pearson correlation coefficients between baseline
- 217 covariates were estimated using the R function *cor.test*.

218 Bayesian hierarchical model to estimate viral clearance rates

- 219 The analysis of the serial viral density data used the same core analytical model as in previous publications [5,
- 13–16]. We characterised oropharyngeal viral clearance under a single exponential decay model (linear decay
- on the log scale). Under this model, the rate of viral clearance is defined as the slope parameter of a linear fit
- to the serial log viral density measurements.
- 223 The general model likelihood takes the following form:

224
$$y_{i,j,t} \sim \text{Student-t}(\lambda, a_0 + a_i + a_{\text{cov}} + \gamma x_{i,j,t} + b_0 e^{b_i + b_{cov} + b_{T(i)}} t, \sigma^2)$$

- 225 where:
- $y_{i,j,t}$ is the log viral density (log₁₀ genomes per mL) for the *j*-th swab of patient *i* at time *t*.
- *T*(*i*) is the randomized treatment allocation for individual *i*.
- σ^2 is the variance of the residual error in the model fit; λ is the degrees of freedom for the Student-t error model.
- *a*₀ and *b*₀ are the population mean intercept (baseline viral density) and slope (viral clearance rate),
 respectively.
- *a_i* and *b_i* are the individual random effects on the intercept and slope, respectively.
- a_{cov} and b_{cov} are the linear covariate effects on the intercept and slope, respectively.
- $x_{i,j,t}$ is the human RNase P CT (scaled to have mean 0) for the *j*-th swab from patient *i* at time *t*, with a γ parameter adjusting for the effect of human RNase P on the estimated viral density in the oropharyngeal eluates.
- Covariate terms for the slope and intercept were the reported days since symptom onset, study site, age, sex, and number of vaccine doses received. This model parameterised the treatment effect relative to a reference intervention (e.g. no study drug) as a proportional change $(e^{bT(i)})$. As a sensitivity analysis, we parameterised the treatment effect as an additive change $(b_0 e^{b_i + b_{cov}} + b_{T(i)})$. Model comparison was done using leave-oneout as implemented in the package *loo* version 2.6.0 [23].
- 242

All viral densities below the lower limit of quantification (defined as a CT value of 40) were treated as leftcensored (the likelihood is the integral of the likelihood function below the censoring value). The linear model fitted to data between days 0 and T_{max} (T_{max} was 7 days in the primary analysis) estimates the average clearance rate over T_{max} days. We denote this as α_{0-Tmax} .

247

All models were fitted using weakly informative priors on all parameters (appendix pages 5-6). These priors help computational convergence but have no effect on the parameter estimates (we showed this in previous analyses [13]). In previous analyses we also used a nonlinear 'up-down' model (linear increase followed by linear decrease), but this also had no effect on treatment effect estimates [13].

252

253 Temporal changes in viral clearance dynamics

254 To assess the temporal changes in viral clearance we added a penalised B-spline of degree 4 to the population 255 mean intercept a_0 (baseline viral density) and population mean slope b_0 (population viral clearance rate) in the 256 reference arm (for most analyses this is the no study drug arm). This was done by having many knots at regular intervals (20 knots in the main analysis) with an informative penalisation prior on parameter changes across 257 258 knots. The penalisation prior governs the smoothness of the spline fit 259 (https://github.com/milkha/Splines_in_Stan).

260 Meta-analysis of treatment effects

261 The interventions studied (ivermectin, remdesivir, favipiravir, molnupiravir, ritonavir-boosted nirmatrelvir, and 262 casirivimab/imdevimab) were not randomised concurrently (appendix page 8). Thus, the large observed 263 temporal changes in baseline viral clearance rates bias cross-comparisons. We adjusted for temporal 264 confounding by explicitly incorporating into the model the temporal changes in viral clearance rates in the 265 treatment effect estimation. We fitted the full Bayesian linear model with a spline term on the baseline 266 clearance rate in the no study drug arm (which spans the entire study period) as a function of the calendar 267 date, with treatment effects parameterised as proportional changes in the average clearance. As a sensitivity 268 analysis, we assessed treatment effect heterogeneity with respect to the SARS-CoV-2 major lineages. This was 269 done by incorporating interaction terms between the intervention and the and viral lineage.

270

281

271 Optimal design

272 In light of the substantial changes observed in the viral clearance rates α_{0-7} in COVID-19 over the past two 273 years, we used the available comparative data to assess the optimal trial design for pharmacometric 274 assessment and thus the rapid identification and evaluation of effective antivirals. We define 'optimal' as the 275 design (duration and frequency of sampling) which maximises the expected z-score for differences in viral 276 clearance rates when comparing an effective randomised intervention with the concurrent no treatment arm 277 or comparing two concurrently randomised interventions with different antiviral efficacies. The z-score is the 278 estimated effect size divided by the estimated standard error. We bootstrapped the data (sampling patients in 279 each comparison with replacement) to obtain uncertainty intervals for the z-score estimates for each 280 comparison. In order for the z-scores to be comparable, each bootstrap sample contained 50 patients per arm.

282 The following designs were compared:

- Varying the duration of follow-up from 2 days (i.e., using qPCR measurements taken on days 0, 1 and 2)
 to 14 days (using all available qPCR data);
- Varying the number of swabs taken each day (1 or 2);
- Comparing twice daily swabs taken on days 0 to 4 (10 qPCR measurements), versus twice daily every other day (0, 2, and 4: 6 qPCR measurements), versus twice daily only on days 0 and 4 (4 qPCR measurements).
- 289 Empirical expected z-scores were estimated under the linear model for six separate intervention comparisons 290 (each comparison used concurrently randomised patients): remdesivir versus no study drug; 291 casirivimab/imdevimab versus no study drug; molnupiravir versus no study drug; ritonavir boosted nirmatrelvir 292 versus no study drug; and ritonavir-boosted nirmatrelvir versus molnupiravir. The data for ritonavir-boosted 293 nirmatrelvir versus no study drug spanned 16 months with a brief hiatus in recruitment from January to 294 February 2023. We therefore arbitrarily split these data into two separate comparisons, before January 2023 and after February 2023. This allowed assessment of how much the temporal change in viral clearance was 295 296 driving the observed results. For each of these six comparisons, and each sampling design (duration of follow-297 up and number of samples), we bootstrapped the data 50 times (sampling the patients with replacement) and 298 fitted the linear model to estimate the treatment effect and standard error.
- 299 Analysis code

All Bayesian models are written in stan and fitted using the *rstan* interface version 2.32.3 [24]. All analyses were done using R programming language version 4.3.2 [25].

302

303 Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

306 **Results**

307 Patient cohort

Between the 29th September 2021 and 20th October 2023, 1262 patients were randomised in the PLATCOV trial 308 309 across six sites in four countries (Thailand, Brazil, Pakistan, and Laos). Patients randomised to ensitrelvir, the 310 combination treatment of ritonavir-boosted nirmatrelvir and molnupiravir, and nitazoxanide were not included 311 in this analysis as these comparisons are ongoing and their data are still blinded (Figure 1). Patients randomised 312 to fluoxetine and tixagevimab/cilgavimab were not included as their data had not been published at the time 313 of the analysis [26]. After excluding patients who withdrew consent, or who were not SARS-CoV-2 positive on 314 any follow-up samples, or who had fewer than 2 days follow-up, the analysis population consisted of 800 315 patients randomised across seven arms (not all concurrently, see appendix page 8). Nearly all included patients 316 had received at least one vaccine dose (>98%) and the majority were fully vaccinated (>88%) prior to symptom 317 onset (Table 1; appendix page 9). The majority (85%) of patients were randomised at one site in Thailand 318 (Hospital for Tropical Diseases, Bangkok). The mean time from symptom onset to randomisation was 2.1 days 319 (standard deviation [SD]: 0.8) and the geometric mean baseline viral density in oropharyngeal eluates was approximately 5.5 log₁₀ genomes per mL (SD: 1.2). Nearly all patients had complete viral density data between 320 days 0 and 7 (less than 5% missing data in all intervention arms, see appendix page 10). 321







324

Figure 1: PLATCOV trial profile and selection of patients used in this analysis. This analysis includes patients enrolled between 30th September 2021 and 20th October 2023 who met the modified intention to treat (mITT) criteria and whose viral clearance data have been unblinded and published. Patients are only excluded from the mITT if protocol deviations occur on days 0 to 2.

- 329
- 330
- 331

332 **Baseline viral densities**

333 The baseline oropharyngeal eluate viral densities remained high over the two-year period (appendix page 11) 334 but there were systematic trends over time associated with different SARS-CoV-2 variants. The reported 335 interval since symptom onset was negatively correlated with the baseline viral density (correlation coefficient 336 ρ = -0.22 [95% confidence interval (CI): -0.29 to -0.16]; R^2 = 0.05) (Figure 2A). Each reported additional day 337 since symptom onset corresponded to a 1.9-fold [95% Crl: 1.5 to 2.4] decrease in the baseline viral density; 338 and males had 1.4-fold [95% Crl: 1.0 to 2.1] higher baseline viral load densities (appendix page 12). There were small changes in the mean reported number of days since symptom onset over time. For example, during the 339 Omicron BA.1 wave (1st January 2022 to 11th March 2022) patients were recruited slightly later on average, 340 Figure 2B. In a multivariable spline model stratified by the interval since symptom onset, there was evidence 341 342 of systematic temporal changes in baseline viral density over time which were not explained by differences in 343 time from symptom onset (Figure 2C). As these are observational data it is not possible to determine causality 344 (e.g., whether these differences result from variant specific mutations in the spike protein) but the data are compatible with higher peak viral densities with specific variants such as BA.2 and XBB.1.5-like.





349 Figure 2: Changes in symptoms duration at enrollment and baseline viral densities over a two year period (2021-2023). 350 Panel A: relationship between reported time since symptom onset and baseline viral density; panel B: temporal changes 351 in the reported time since symptom onset. The vertical dashed line indicates the first Omicron BA.1 infection enrolled in 352 the study; panel C: temporal changes in the baseline viral density stratified by reported time since symptom onset. Red 353 lines (shaded areas) represent mean estimated values (95% confidence intervals) under a generalised additive model.

Table 1: Baseline demographics for the 800 patients included in the analysis. Unless specified, data are shown as *n* (%); †mean (standard deviation); ‡median (interquartile range).

		No study drug (n=263)	Ritonavir- boosted nirmatrelvir (n=158)	Favipiravir (n=114)	Casirivimab/ imdevimab (n=88)	Remdesivir (n=67)	Molnupiravir (n=66)	lvermectin (n=44)
В	razil	26 (10)	4 (3)	16 (14)	0	9 (13)	0	0
Т	hailand	230 (88)	150 (95)	98 (86)	88 (100)	58 (87)	65 (99)	44 (100)
La	aos	3 (1)	4 (3)	0	0	0	1 (2)	0
P	akistan	4 (2)	0	0	0	0	0	0
A	ge (years)†	31.1 (8.1)	31.3 (8.9)	30.2 (7.5)	27.9 (7.3)	30.1 (8.2)	31.3 (7.5)	30.0 (7.0)
F	emale	173 (66)	109 (69)	71 (62)	55 (62)	35 (52)	37 (56)	24 (55)
V (ł	Veight ‹g)†	63.0 (13.6)	61.5 (12.3)	63.0 (13.6)	60.4 (12.3)	63.9 (11.0)	63.4 (14.7)	61.6 (12.3)
В	MI†	23.2 (4.1)	23.0 (3.8)	23.1 (3.7)	22.1 (3.1)	22.7 (3.1)	23.1 (4.0)	22.3 (3.2)
lr sy o	nterval since ymptom nset (days)‡	2 (1-3)	2 (1-2)	2 (2-3)	2 (2-3)	2.5 (2-3)	2 (2-2)	2 (2-3)
A Ic gʻ	dmission viral oad (log10 enomes/mL)‡	5.6 (4.7-6.4)	5.6 (4.6-6.4)	5.5 (4.7-6.2)	5.7 (5.0-6.4)	5.3 (4.8-6.3)	5.8 (5.0-6.4)	5.6 (5.0-6.6)
V	accinated (%)	253 (96)	153 (97)	112 (98)	85 (97)	64 (96)	65 (99)	43 (98)
S	tart date	Sep 29, 2021	Jun 5, 2022	Oct 10, 2021	Oct 1, 2021	Oct 4, 2021	Jun 5, 2022	Sep 29, 2021
Fi	inish date	Oct 20, 2023 (ongoing)	Oct 20, 2023 (ongoing)	Oct 29, 2022	Oct 19, 2022	Jun 7, 2022	Feb 14, 2022	Apr 11, 2022
S. Vi	ARS-CoV-2 ariants							
D	elta	10 (4)	0	11 (10)	13 (15)	10 (15)	0	12 (27)
В	A.1	13 (5)	0	21 (18)	15 (17)	20 (30)	0	14 (32)
В	A.2	52 (20)	1 (1)	42 (37)	30 (34)	37 (55)	5 (8)	18 (41)
В	A.2.75	43 (16)	30 (19)	5 (5)	5 (6)	0	28 (42)	0
В	A.4	2 (1)	3 (2)	3 (3)	0	0	2 (3)	0
В	A.5	42 (16)	26 (17)	32 (28)	25 (28)	0	28 (42)	0
Х	BB	29 (11)	22 (14)	0	0	0	3 (5)	0
х	BB.1.5-like	67 (26)	75 (48)	0	0	0	0	0
0	ther	5 (2)	1 (2)	0	0	0	0	0

359 Viral clearance rates over time

360 Viral clearance increased substantially over the two years of the trial, as shown clearly in patients randomised 361 to no study drug (appendix page 13). Figure 3 shows the individual clearance rate estimates α_{0-7} under the hierarchical Bayesian model with a spline term to capture temporal changes. In the no study drug arm, median 362 363 viral clearance rates have doubled approximately from -0.43 log₁₀ units per day in September 2021 364 (corresponding to a half-life of around 16.6 hours [interquartile range (IQR): 15.3 to 18.2]), to -0.78 log₁₀ units 365 per day in October 2023 (half-life of around 9.2 hours; IQR: 8.0 to 10.6). This change corresponds to a relative 366 shortening in viral clearance half-life of 44% [95% credible interval [Crl]: 19 to 64%] over two years. Similar 367 trends were noted for the treated individuals. For example, the mean viral clearance rate in the ritonavirboosted nirmatrelvir arm increased from -1.12 log₁₀ units per day in June 2022 (half-life of 6.4 hours; IQR: 5.7 368 369 to 7.3) to -1.50 log₁₀ units per day in October 2023 (half-life of 4.8 hours; IQR: 4.2 to 5.5). This change 370 corresponds to a relative shortening in viral clearance half-life of 26% [95%Crl: -4 to 42%]. The reduction of 371 viral clearance half-life was most apparent early in the study between September 2021 (Delta variant) to in 372 mid-February 2022 (BA.2 variant, appendix page 14). Subsequently, the half-life plateaued at around 12.5 373 hours during the BA.2, BA.4, BA.5, and BA.2.75 variants, and gradually reduced again after the emergence of 374 XBB and XBB.1.5-like variants in January 2023. There was no clear relationship between individual viral 375 clearance rate estimates and the number of days since symptom onset, sex, age, or the number of vaccine 376 doses received (appendix page 12).





378

Figure 3: Individual patient data meta-analysis of the platform trial showing estimated rates of viral clearance between days 0 and 7 (α 0–7). Average clearance rates for each intervention (coloured lines) and the no study drug arm (black line) are estimated from a spline fit. Treatment effects were parameterised as a proportional change in rate. The grey circles and black lines for the no study drug arm are identical in each panel. Vertical lines show 95% credible intervals under the linear model. A negative sign of the clearance rate indicates a decreasing directional change in viral density.

385 **Optimising trial design**

386 Figure 4 shows the expected z-scores for 6 randomised comparisons with a sample size of n=50 per arm as a 387 function of the duration of follow-up data included in the estimated viral clearance rate (varying from day 2 until day 14). For all pairwise comparisons there was a clear inverted-parabolic relationship between the 388 389 expected z-score and the duration of follow-up. The expected z-score was maximised for durations between 4 390 and 5 days. This implies that 4-5 days follow-up is optimal in terms of power when the data are analysed under 391 a linear model framework. Fitting a single component log-linear model over a longer time period systematically 392 reduced the estimate of the slope (i.e., lengthens the half-life) as it incorporated more of the slower β -phase 393 (second phase) of viral elimination in the estimate. Additional analyses highlighted the importance of taking 394 duplicate oropharyngeal swabs (appendix page 15). Reducing the frequency of the viral density measurements 395 reduced the expected z-score but with a lesser effect.





397

Figure 4: Z-scores for the six treatment effects as a function of the follow-up duration. The boxplots show the median and 398 399 interquartile range of the z-scores for the 50 bootstrap iterations. Each bootstrap adatset contained 50 patients per arm. 400 The red vertical dashed lines indicate the follow-up durations with maximal z-scores. All comparisons use concurrent 401 controls only.

402 Comparative assessment of antiviral interventions

403 Under the linear model with adjustment for temporal changes in clearance rates, there was a clear hierarchy 404 between the studied interventions (Figure 5). This hierarchy remained consistent when estimating treatment 405 effects using the average viral clearance rates up until day 5 (α_{0-5}) or up until day 7 (α_{0-7}). Ritonavir-boosted 406 nirmatrelvir had the greatest effect on viral clearance rates (approximately 90% increase in average clearance 407 rates α_{0-7} ; approximately 130% increase in average clearance rates α_{0-5}). The small molecule drugs remdesivir 408 and molnupiravir had very similar effects (approximately 35% increase in average clearance rates α_{0-7} ; 409 approximately 50 to 60% increase in average clearance rates α_{0-5}). The average treatment effect for the

410 monoclonal antibody casirivimab/imdevimab was of similar magnitude (ignoring known treatment effect 411 heterogeneity [14]). This meta-analysis confirmed the absence of any measurable effect of high-dose 412 ivermectin or high-dose favipiravir. For all four effective interventions, the analysis using the α_{0-5} average 413 clearance rates estimated substantially larger effect sizes, albeit with slightly wider uncertainty intervals. There 414 was no evidence of treatment effect heterogeneity for the small molecule drugs by viral variants, whereas the 415 effect of casirivimab/imdevimab varied considerably across the major viral variants (appendix page 16).

- 416
- 417



418

Figure 5: Individual patient 6data meta-analysis of the treatment effect of the six randomised interventions relative to no study drug. Red: treatment effects based on the average clearance rates over 5 days (α_{0-5}); blue: treatment effects based on the average clearance rates over 7 days (α_{0-7}). The models explicitly adjusted for temporal changes in viral clearance in the no study drug arm using penalised B-splines. Points: median posterior estimate; thick and thin lines: 80% and 95% credible intervals, respectively.

425 Discussion

426 SARS-CoV-2 oropharyngeal clearance rates in uncomplicated COVID-19 infections have become substantially 427 faster over the past two years. Natural viral clearance is now twice as fast as it was in September 2021. This 428 very granular prospectively gathered dataset confirms the findings of other larger scale observational cohorts 429 [27]. In this studied cohort, most of whom were fully vaccinated, waves of different viral variants succeeded 430 each other, following a generally similar pattern to that observed in most areas of the world. There was no 431 clear association between particular viral variants and increases in viral clearance rates. Instead, there appears 432 to have been a steady increase in clearance rates across all variants over time. Some variants (e.g., BA.2.75) 433 were clearly associated with higher baseline viral densities, which was not explained by differences in the 434 interval from symptom onset. It is not possible to ascribe with confidence the underlying cause for these higher 435 baseline viral loads, but it would be compatible with either differences in viral replication [28] or differences 436 in tropism [29].

437

438 The substantial acceleration in natural viral clearance over the past two years presumably reflects the interplay 439 between the acquisition of immunity and the antigenic changes in the evolving variants. This acceleration in 440 natural viral clearance has important implications for the assessment of in-vivo antiviral activity. SARS-CoV-2 441 oro/nasopharyngeal clearance is biphasic [17–19]. Effective drugs substantially accelerate the first phase. Two 442 years ago, when viral clearance rates were much slower, the inflexion in the clearance curve (transition from 443 the first to the second slower phase) was close to seven days, so fitting a single rate constant to the log-linear 444 decline in viral densities over seven days incurred relatively little bias. At current rates of viral clearance, the 445 inflexion point is much earlier, so forcing a single rate constant to the serial qPCR values over seven days incurs 446 greater bias resulting in progressive underestimation of the initial phase rate of clearance. This is important 447 for historical comparisons of antiviral activity as, with any viral clearance measure, drugs today will result in 448 faster viral clearance than they did earlier in the pandemic. Moderately effective drugs evaluated two years 449 ago (e.g., remdesivir) resulted in viral clearance rates that are similar to those in the no treatment arm of the 450 study today.

451

452 The PLATCOV study has characterised the effect of several antiviral drugs with findings which are generally 453 consistent with earlier clinical trials assessing their efficacy in the prevention of disease progression. 454 Comparative estimates of in vivo antiviral activity allow for rational selection of drugs now that comparison 455 based on clinical endpoints is no longer possible because of the prohibitively large sample sizes required in 456 clinical trials. Using the observed differences in the viral clearance profiles between effective and ineffective 457 drugs or the no treatment arm allowed determination of the sampling duration which best characterised these 458 differences. The greatest differences between effective and ineffective (or no) drugs were observed for 459 assessments made from serial samples taken over 4-5 days. Although there is substantial inter-individual 460 variation in clearance rates, and also intra-individual variation between the serial viral density estimates, with 461 current viral clearance rates daily sampling still has adequate discriminatory power. But, if this trend of 462 increasing rapidity of viral clearance continues, then it may be necessary to sample twice daily over a shorter 463 period. Shortening the viral clearance serial sampling to five days simplifies the comparative assessment of 464 antiviral drugs in COVID-19 (although later sampling is still necessary if rebound is being assessed).

465

These data emphasise the critical importance of fixed ratio contemporary comparators in platform trials. Temporal confounding across non-currently randomised interventions or for time varying randomisation ratios (this occurs in response adaptive trials) requires model dependent adjustment. Even an ineffective drug will appear effective if compared with a historical control. The exact ranking of all unblinded interventions studied on the platform in the meta-analysis is dependent in part on correct adjustment for the temporal trends. This issue is particularly salient for the comparison between remdesivir and molnupiravir.

473 SARS-CoV-2 is today predominantly a mild infection in vaccinated individuals which does not require specific 474 antiviral treatment. This justifies the recruitment of patients into the pharmacometric assessment who receive no specific treatment. But in patients with underlying conditions or the elderly, COVID-19 is still potentially 475 476 dangerous and specific antiviral treatment is required. There is no reason to believe that antiviral activities are 477 different in these high-risk subgroups to those observed in low-risk patients enrolled in this study. At the 478 beginning of the pandemic there were no effective interventions and so identifying minor accelerations in viral 479 clearance was relevant. Today modest acceleration in the rate of viral clearance may still be therapeutically 480 relevant for chemoprevention [26], but it is very unlikely that less effective drugs than those now being used 481 would be deployed for the treatment of symptomatic COVID-19. The simple methodology employed in the 482 PLATCOV trial is efficient, and very well tolerated, and it identifies efficacious antivirals (i.e., those which result 483 in viral clearance rates that are >20% faster than no drug) with sample sizes which are usually less than 40 484 studied patients per arm.

485

497

486 Although this is the largest detailed pharmacometric study in COVID-19, it has some limitations. Most of the 487 patients were studied in Bangkok, Thailand so the temporal trends observed could be different in other parts 488 of the world. The cause of the substantial inter-patient variations in viral clearance and the overall acceleration 489 in viral clearance over the past two years has not been characterised adequately. Over 95% of patients were 490 vaccinated before the enrolment infection and so we cannot characterise differences in treatment effects 491 between vaccinated and unvaccinated individuals. Although there is a clear rationale for using viral clearance 492 as a surrogate endpoint in assessing therapeutics [8, 9], additional data are still needed to characterise the 493 relationship between acceleration in viral clearance and clinical outcomes such as rate of symptom clearance. 494

- In summary, SARS-CoV-2 viral clearance has accelerated substantially over the past two years necessitating a
 shortening of the sampling time to evaluate and compare antiviral drugs efficiently.
- 498 Acknowledgements

499 NJW is a Principal Research Fellow funded by the Wellcome Trust (093956/Z/10/C). JAW is a Sir Henry Dale 500 Fellow funded by the Wellcome Trust (223253/Z/21/Z). This study is supported by Wellcome Trust grant 501 reference 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator. We thank all the patients with 502 COVID-19 who volunteered to be part of the study. We thank the data safety and monitoring board (Tim Peto, 503 André Siqueira, and Panisadee Avirutnan); the trial steering committee (Nathalie Strub-Wourgaft, Martin 504 Llewelyn, Deborah Waller, and Attavit Asavisanu); Sompob Saralamba and Tanaphum Wichaita for developing 505 the Rshiny randomisation app; and Mavuto Mukaka for invaluable statistical support. We also thank all the 506 staff of the clinical trials unit at MORU, Thermo Fisher for their excellent support with this project, and all the 507 hospital staff at the Hospital for Tropical Diseases, as well as those involved in sample processing in MORU and 508 the processing and analysis at the Faculty of Tropical Medicine, Mahidol University, molecular genetics 509 laboratory, and the malaria laboratory. We thank the Department of Medical Services, Ministry of Public 510 Health, Thailand for the generous support and the donation of the molnupiravir and ritonavir-boosted 511 nirmatrelvir for this study. We thank the MORU Clinical Trials Support Group for data management, monitoring 512 and logistics, and the purchasing, administration and support staff at MORU.

- 513
- This research was partly funded by Wellcome. A CC BY or equivalent licence is applied to the author accepted
 manuscript arising from this submission, in accordance with the grant's open access conditions.
- 516
- 517 Authorship contributions

518 PW: conceptualisation, data curation, formal analysis, methodology, visualisation and writing original draft; 519 WHKS: conceptualisation, funding acquisition, investigation, methodology, project administration, supervision, 520 validation and writing- original draft; NJW: conceptualisation, funding acquisition, methodology, supervision, 521 validation and writing- original draft; JAW: conceptualisation, data curation, formal analysis, funding 522 acquisition, methodology, visualisation and writing original draft; PJ: investigation, methodology, project administration, supervision, and validation; SB, and SS: investigation, methodology and project administration; 523 524 VL, TS, TN, BH, and KP: investigation, methodology, and supervision; EMB: data curation, and formal analysis; 525 JK, WPa, and PK: investigation, methodology; MM, and EAA: investigation, supervision, funding acquisition; KC 526 and MI: formal analysis, investigation, resources, supervision; SP, AMD, MMT, WPi, WPh: methodology, 527 investigation, resources, supervision; NPJD: funding acquisition, methodology, investigation, resources, 528 supervision. All authors were involved in writing, review, and editing of the manuscript. PW, WHKS, EMB, MI, 529 NJW, JAW have directly accessed and verified the underlying data reported in the manuscript. All authors had 530 full access to all the data in the study and had final responsibility for the decision to submit for publication.

531

532 Data Sharing

533 All data and code necessary to reproduce the results in this analysis are openly available at 534 <u>https://github.com/jwatowatson/Determinants-viral-clearance</u>

535

All code and de-identified participant data required for replication of the study's endpoints are openly accessible via Zenodo, as well as the study protocol and statistical analysis plan, from publication date onwards. Individual patient data can be requested and may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future from the date of publication. Further information on how to apply is on the MORU Tropical Health Network site.

541

542 **Declaration of interests**

543 We declare no competing interests.

544 **References**

- 545 1. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV Antibody Combination
 546 and Outcomes in Outpatients with Covid-19. N Engl J Med. 2021;385(23):e81.
- 547 2. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early Remdesivir to Prevent Progression to
 548 Severe Covid-19 in Outpatients. N Engl J Med. 2022 Jan 27;386(4):305–15.
- 549 3. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for High-550 Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397–408.
- 4. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir
- 552 for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386(6):509–20.
- 553 5. Schilling WHK, Jittamala P, Watson JA, Boyd S, Luvira V, Siripoon T, et al. Antiviral efficacy of molnupiravir 554 versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label,
- phase 2, randomised, controlled, adaptive trial. Lancet Infect Dis. 2024 Jan 1;24(1):36–45.
- 5566. Yotsuyanagi H, Ohmagari N, Doi Y, Yamato M, Bac NH, Cha BK, et al. Efficacy and Safety of 5-Day Oral557Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial. MedRxiv558Prepr[Internet].2023;Availablefrom:
- 559 <u>https://www.medrxiv.org/content/early/2023/07/13/2023.07.11.23292264</u>
- 7. Parienti JJ, de Grooth HJ. Clinical relevance of nasopharyngeal SARS-CoV-2 viral load reduction in outpatients
 with COVID-19. J Antimicrob Chemother. 2022 Apr;77(7):2038–9.
- 562 8. Elias KM, Khan SR, Stadler E, Schlub TE, Cromer D, Polizzotto MN, et al. Viral clearance as a surrogate of
- clinical efficacy for COVID-19 therapies in outpatients: A systematic review and meta-analysis. MedRxiv Prepr.
 2023;2023–06.
- 565 9. Singh S, Boyd S, Schilling W, Watson JA, Mukaka M, White NJ. The relationship between viral clearance rates
- and disease progression in early symptomatic COVID-19; a systematic review and meta-regression analysis. J
- 567 Antimicrob Chemother. 2024; dkae045.

- 568 10. World Health Organization. Statement on the Fifteenth Meeting of the International Health Regulations 569 (2005) Emergency Committee regarding the Coronavirus Disease (COVID-19) Pandemic [Internet]. 2023. 570 https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-Available from: 571 international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-572 pandemic. Date accessed: February 9, 2024. 573 11. Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual 574 care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes 575 (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. The Lancet. 2023 Jan 576 28;401(10373):281-93. 577 12. Watson JA, Kissler SM, Day NPJ, Grad YH, White NJ. Characterizing SARS-CoV-2 Viral Clearance Kinetics to 578 Improve the Design of Antiviral Pharmacometric Studies. Antimicrob Agents Chemother. 2022 Jul 579 19;66(7):e00192-22. 580 13. Schilling WHK, Jittamala P, Watson JA, Ekkapongpisit M, Siripoon T, Ngamprasertchai T, et al. 581 Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled 582 adaptive platform trial (PLATCOV). eLife. 2023 Feb 21;12:e83201. 583 14. Jittamala P, Schilling WHK, Watson JA, Luvira V, Siripoon T, Ngamprasertchai T, et al. Clinical antiviral efficacy 584 of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants. MedRxiv Prepr. 585 2022;2022-10. 586 15. Luvira V, Schilling WHK, Jittamala P, Watson JA, Boyd S, Siripoon T, et al. Clinical antiviral efficacy of favipiravir 587 in early COVID-19 (PLATCOV): an open-label, randomised, controlled adaptive platform trial. BMC Infect Dis. 588 2024;24:89 589 16. Jittamala P, Schilling WHK, Watson JA, Luvira V, Siripoon T, Ngamprasertchai T, et al. Clinical Antiviral Efficacy 590 of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial 591 (PLATCOV). J Infect Dis. 2023 Jul 20; jiad275. 592 17. Néant N, Lingas G, Le Hingrat Q, Ghosn J, Engelmann I, Lepiller Q, et al. Modeling SARS-CoV-2 viral kinetics 593 and association with mortality in hospitalized patients from the French COVID cohort. Proc Natl Acad Sci. 2021 594 Feb 23;118(8):e2017962118. 595 18. Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. Daily longitudinal sampling of SARS-CoV-2 596 infection reveals substantial heterogeneity in infectiousness. Nat Microbiol. 2022 May 1;7(5):640-52. 597 19. Ribeiro RM, Choudhary MC, Deo R, Giganti MJ, Moser C, Ritz J, et al. Variant-Specific Viral Kinetics in Acute 598 COVID-19. J Infect Dis. 2023 Aug 31;228(Supplement 2):S136-43. 599 20. Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs RW, et al. Antiviral and clinical activity of bamlanivimab 600 in a randomized trial of non-hospitalized adults with COVID-19. Nat Commun. 2022 Aug;13(1):4931. 601 21. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using Ime4. J Stat Softw. 2015 602 Oct 7;67(1):1-48. 603 22. Wood SN. Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric 604 generalized linear models. J R Stat Soc Ser B Stat Methodol. 2011 Jan;73(1):3–36. 605 23. Vehtari A, Gelman A, Gabry J. Practical Bayesian model evaluation using leave-one-out cross-validation and 606 WAIC. Stat Comput. 2017 Sep 1;27(5):1413-32. 607 24. Stan Development Team. RStan: the R interface to Stan [Internet]. 2023. Available from: https://mc-608 stan.org/ 609 25. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R 610 Foundation for Statistical Computing; 2023. Available from: https://www.R-project.org/ 611 26. Podjanee Jittamala, Simon Boyd, William HK Schilling, James A Watson, Thundon Ngamprasertchai, Tanaya 612 Siripoon, et al. Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, 613 controlled, adaptive platform trial (PLATCOV). medRxiv. 2024 Jan 1;2024.01.16.24301337. 614 27. Lin Y, Wu P, Tsang TK, Wong JY, Lau EHY, Yang B, et al. Viral kinetics of SARS-CoV-2 following onset of COVID-
- 615 19 in symptomatic patients infected with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective
- observational study. Lancet Microbe. 2023 Sep 1;4(9):e722–31.

- 617 28. Marc A, Marlin R, Donati F, Prague M, Kerioui M, Hérate C, et al. Impact of variants of concern on SARS-
- 618 CoV-2 viral dynamics in non-human primates. PLOS Comput Biol. 2023 Aug;19(8):1–16.
- 619 29. Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, et al. Altered TMPRSS2 usage by
- 620 SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022 Mar 1;603(7902):706–14.



Excluded (n = 49)

- Chronic illness (n = 12)
- Lab abnormalities (n = 27)
- Taking concomitant medications (n = 7)
- Other (n = 3)

Randomised to other interventions (n = 389)

- Fluoxetine (n = 120)
- Ensitrelvir (n = 95)
- Tixagevimab/cilgavimab (n = 96)
- Ritonavir-boosted nirmatrelvir + Molnupiravir (n = 44)
- Nitazoxanide (n = 34)

Excluded from analysis (n = 24)

Non-compliance with study procedures prior to day 2 (n = 8)

- Withdrawn as given rescue medications (n = 2)
- Withdrawn due to side-effects (n = 2)
- Withdrew consent for other reasons (n = 4)
 Withdrew consent before starting interventions (n = 11)
 Undetectable viral loads (n = 5)



C Temporal dynamics of baseline viral densities by time since symptom onset





Randomisation date





Days follow-up included

Z-score

